Posted by Michael Wonder on 01 Jun 2021
Mycovia Pharmaceuticals submits new drug application to the U.S. FDA for oteseconazole for the treatment of recurrent vulvovaginal candidiasis
1 June 2021 - Oteseconazole’s qualified infectious disease product and fast track designations allow for six month priority review by FDA following its acceptance of the NDA.
Mycovia Pharmaceuticals today announced it has submitted its new drug application for oteseconazole, an oral anti-fungal product for the treatment of recurrent vulvovaginal candidiasis.
